590 related articles for article (PubMed ID: 27203439)
1. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Torikai H; Cooper LJ
Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
[TBL] [Abstract][Full Text] [Related]
2. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
4. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
[TBL] [Abstract][Full Text] [Related]
5. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
6. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
7. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
Stauss HJ; Morris EC
Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
[TBL] [Abstract][Full Text] [Related]
9. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cell therapy: 25years in the making.
Gill S; Maus MV; Porter DL
Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
[TBL] [Abstract][Full Text] [Related]
11. Off the shelf T cell therapies for hematologic malignancies.
McCreedy BJ; Senyukov VV; Nguyen KT
Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
[TBL] [Abstract][Full Text] [Related]
12. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
13. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Li H; Zhao Y
Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
[TBL] [Abstract][Full Text] [Related]
14. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
15. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
[TBL] [Abstract][Full Text] [Related]
16. Designing chimeric antigen receptors to effectively and safely target tumors.
Jensen MC; Riddell SR
Curr Opin Immunol; 2015 Apr; 33():9-15. PubMed ID: 25621840
[TBL] [Abstract][Full Text] [Related]
17. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
[TBL] [Abstract][Full Text] [Related]
18. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
Watanabe N; Mamonkin M
Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
[TBL] [Abstract][Full Text] [Related]
19. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
20. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]